Table 4.

Results of the ordinal regression model for pot-COVID-19 follow-up phase substance use among 993 individuals who had mild COVID-19 in São Caetano do Sul, SP, Brazil.

Outcome: post-COVID follow-up phase	Alcohol			Tobacco			Cannabis			Non-medical benzodiazepine			Non-medical analgesic
	Coef.	95%CI		Coef.	95%CI		Coef.	95%CI		Coef.	95%CI		Coef.	95%CI
Exposures:
Number of CDC COVID-19 symptoms	0.001	−0.069	0.072	−0.077	−0.259	0.106	−0.191	−0.450	0.069	0.150	0.002	0.298	0.054	−0.013	0.120
Pre-COVID-19 alcohol use	1.956***	1.783	2.128	0.129	−0.143	0.402	0.084	−0.319	0.487	−0.030	−0.269	0.209	0.099*	0.004	0.194
Pre-COVID-19 tobacco use	0.070	−0.005	0.144	1.613***	1.387	1.840	0.247*	0.038	0.456	0.053	−0.159	0.265	−0.036	−0.117	0.045
Pre-COVID-19 cannabis use	−0.044	−0.196	0.107	−0.082	−0.321	0.156	2.325***	1.862	2.788	−0.460*	−0.896	−0.023	0.120	−0.037	0.276
Pre-COVID-19 Non-medical benzodiazepines use	−0.101	−0.293	0.090	−0.121	−0.443	0.200	−0.908**	−1.540	−0.276	1.221***	0.990	1.452	0.167*	0.010	0.325
Pre-COVID-19 Non-medical analgesics use	0.042	−0.061	0.145	−0.064	−0.296	0.168	0.181	−0.146	0.508	0.315**	0.104	0.527	1.401***	1.274	1.528

All the models adjusted for gender, age, city suburb, civil status, educational level, income, previous medical diseases, previous psychiatric disorder, time between intake and assessment.

^*p < 0.05;

^**p < 0.01;

^***p < 0.001.